Citigroup Maintains Buy on Applied Therapeutics, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz has maintained a Buy rating on Applied Therapeutics (NASDAQ:APLT) and raised the price target from $8 to $11.
September 19, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup has reaffirmed its Buy rating on Applied Therapeutics and increased the price target from $8 to $11, indicating confidence in the company's future performance.
The increase in price target from $8 to $11 by Citigroup suggests a positive outlook on Applied Therapeutics' future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100